one stock. Whatever they say, it's either going. It's either going to rip or go somewhere else.But that's it. >> All right. A new bipartisan report out today from the Council on Foreign Relations.The topic U.S. Economic Security and Strategic Competition in Emerging Technologies. Joining us right now is former commerce secretary in the Biden administration, Gina Raimondo. She co-chairs the task force in charge of that report.And, Secretary, thank you for being with us. Watching Washington these days, it's h ...

If you look at the sectors this week, healthcare is up four and a half%. Materials are up three. Financials are up two and a half.Comm services and tech doing just fine. Doing just fine, but they're not the best two or three. They are not.So today we have 30 new S&P 52- week highs. Of those 30 highs, 27 of them are nontechnology. Goldman Sachs, Morgan Stanley, JP Morgan, Gilead, these are the names.American Express, Amgen, you do have your Crowd Strike, your IBM, and your Seagate. So, the battleship of mome ...

Beauty & Wellness Trends - IV drips（静脉滴注）和 biotech powders（生物科技粉末）正在取代 fish oil capsules（鱼油胶囊）和 collagen（胶原蛋白），成为美容爱好者的选择 [1] - 行业关注这些新兴美容方式是否有效 [1]

Core Viewpoint - The biopharmaceutical industry is divided into two main types of companies: biotech and biopharma, which require fundamentally different capabilities [2][3] Group 1: Industry Structure - The biopharmaceutical industry can be segmented into three main capabilities: research and development, clinical trials, and commercialization [2][4] - Biotech companies primarily focus on research and early clinical trials, while biopharma companies possess all three capabilities [3][4] Group 2: Commercialization Dynamics - Clinical and commercialization capabilities are crucial and are often built over many years through trust established with doctors and hospitals [4][5] - The global business model typically involves biotech handling R&D and early clinical trials, while biopharma takes over late-stage clinical trials and commercialization [4][5] Group 3: Value Creation - Biotech companies can create shareholder value through three main avenues: selling products to pharma, selling themselves to pharma, or becoming a pharma company, with the latter being the most challenging [5][6] - Biopharma companies primarily generate value by selling drugs, whether developed in-house or acquired [5][6] Group 4: Success Stories - Examples of companies successfully transitioning from biotech to biopharma include Vertex Pharmaceuticals, Regeneron, and BeiGene, each leveraging a successful drug to establish a strong market position [7][10] - Vertex's KALYDECO and Regeneron's Eylea are highlighted as significant revenue-generating drugs that enabled their respective companies to grow [7][8] Group 5: Market Dynamics - The biopharmaceutical market is characterized by significant price disparities between the U.S. and other regions, with U.S. drug prices being substantially higher [8][9] - The ability to sell drugs in the U.S. is a key indicator of a biopharmaceutical company's potential [8][9] Group 6: Investment Considerations - Companies that can successfully navigate the transition from biotech to biopharma, particularly those with a strong drug pipeline and clear strategic direction, present attractive investment opportunities [12] - Investors should be cautious of companies that lack a clear understanding of their capabilities and market positioning [12][11]